Skip to main content Help with accessibility Skip to main navigation

Shared-care Guidelines

 Click here for a downloadable word document of the shared care agreement forms: 

DMARDs Shared Care Agreement (Version 1.1) 

Generic Shared Care Agreement Form 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 18 - July - 2024

Denosumab 120mg injection - Prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone.

Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 13 - February - 2024

Denosumab 60mg injection - Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of bone loss
associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 13 - February - 2024
BNF chapter: Endocrine system

For hypogonadism due to testosterone deficiency in adult men

Indication (licensed):Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 18 - September - 2024
BNF chapter: Endocrine system

Unlicensed indication: As supplementation for postmenopausal women with low sexual desire if HRT alone is not effective.

***Please note: the shared care guideline for the use of testosterone by postmenopausal women with low sexual desire has been clinically approved by LSCMMG. In the absence of a commissioned service, it is for individual prescribers to assess their own competence to work to the shared care, that appropriate specialist initiation has occurred and that appropriate risk assessments have been undertaken. Please contact mlcsu.medicinesmanagement@nhs.net for further information***

Further patient information is available via the RCOG menopause hub:
https://www.rcog.org.uk/for-the-public/menopause-and-later-life/